Legend Biotech Corporation Stock

Equities

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2024-07-16 EDT 5-day change 1st Jan Change
55.9 USD +3.54% Intraday chart for Legend Biotech Corporation +19.67% -7.10%
Sales 2024 * 542M 742M Sales 2025 * 1.02B 1.39B Capitalization 10.19B 13.93B
Net income 2024 * -323M -442M Net income 2025 * -153M -209M EV / Sales 2024 * 17.2 x
Net cash position 2024 * 855M 1.17B Net cash position 2025 * 727M 994M EV / Sales 2025 * 9.3 x
P/E ratio 2024 *
-53.8 x
P/E ratio 2025 *
-97.8 x
Employees 2,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.54%
1 week+19.67%
Current month+26.21%
1 month+31.68%
3 months+11.53%
6 months-7.37%
Current year-7.10%
More quotes
1 week
47.12
Extreme 47.12
57.82
1 month
40.24
Extreme 40.24
57.82
Current year
38.60
Extreme 38.6
70.13
1 year
38.60
Extreme 38.6
77.32
3 years
30.76
Extreme 30.755
77.32
5 years
23.41
Extreme 23.41
77.32
10 years
23.41
Extreme 23.41
77.32
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 19-06-30
Director of Finance/CFO 53 19-08-31
Chief Tech/Sci/R&D Officer - 18-04-30
Members of the board TitleAgeSince
Chief Executive Officer 51 19-06-30
Director/Board Member 67 20-04-30
Director/Board Member 74 20-11-22
More insiders
Date Price Change Volume
24-07-16 55.9 +3.54% 1,681,963
24-07-15 53.99 -0.70% 2,370,524
24-07-12 54.37 +12.10% 4,891,167
24-07-11 48.5 +2.49% 1,047,018
24-07-10 47.32 +1.31% 271,579

Delayed Quote Nasdaq, July 16, 2024 at 04:00 pm

More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
55.9 USD
Average target price
82.29 USD
Spread / Average Target
+47.22%
Consensus